Switch to:
Abbott Laboratories  (NYSE:ABT) Cash Flow from Financing: $8,335 Mil (TTM As of Sep. 2017)

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Sep. 2017, Abbott Laboratories paid $8 Mil more to buy back shares than it received from issuing new shares. It received $4 Mil from issuing more debt. It paid $0 Mil more to buy back preferred shares than it received from issuing preferred shares. It spent $463 Mil paying cash dividends to shareholders. It received $81 Mil on other financial activities. In all, Abbott Laboratories spent $386 Mil on financial activities for the three months ended in Sep. 2017.


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Abbott Laboratories Annual Data

Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Cash Flow from Financing Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 195.00 -6,696.00 -2,742.00 -2,236.00 11,147.00

Abbott Laboratories Quarterly Data

Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Cash Flow from Financing Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -746.00 13,504.00 -4,399.00 -384.00 -386.00

Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Abbott Laboratories's Cash from Financing for the fiscal year that ended in Dec. 2016 is calculated as:

Abbott Laboratories's Cash from Financing for the quarter that ended in Sep. 2017 is

Cash Flow from Financing(Q: Sep. 2017 )
=Net Issuance of Stock+Net Issuance of Debt+Net Issuance of Preferred Stock+Cash Flow for Dividends+Other Financing
=-8+4+{NetIssuanceofpreferred_last}}+-463+81
=-386

Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2017 was 13504 (Dec. 2016 ) + -4399 (Mar. 2017 ) + -384 (Jun. 2017 ) + -386 (Sep. 2017 ) = $8,335 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Explanation

Cash from financing contains five items:

1. Net Issuance of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. If this number is positive, it means that the company has received more cash from issuing shares than it has paid to buy back shares. If this number is negative, it means that company has paid more cash to buy back shares than it has received for issuing shares.

Abbott Laboratories's net issuance of stock for the three months ended in Sep. 2017 was $-8 Mil. Abbott Laboratories paid $8 Mil more to buy back shares than it received from issuing new shares.

2. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Abbott Laboratories's net issuance of debt for the three months ended in Sep. 2017 was $4 Mil. Abbott Laboratories received $4 Mil from issuing more debt.

3. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Abbott Laboratories's net issuance of preferred for the three months ended in Sep. 2017 was $0 Mil. Abbott Laboratories paid $0 Mil more to buy back preferred shares than it received from issuing preferred shares.

4. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Abbott Laboratories's cash flow for dividends for the three months ended in Sep. 2017 was $-463 Mil. Abbott Laboratories spent $463 Mil paying cash dividends to shareholders.

5. Other Financing:
Money spent or earned by company from other financial activities.

Abbott Laboratories's other financing for the three months ended in Sep. 2017 was $81 Mil. Abbott Laboratories received $81 Mil on other financial activities.


Related Terms


Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK